Vemurafenib
In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation.
Saved in:
| Published in: | Nature reviews. Drug discovery Vol. 10; no. 11; pp. 811 - 812 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
Nature Publishing Group UK
01.11.2011
Nature Publishing Group |
| Subjects: | |
| ISSN: | 1474-1776, 1474-1784, 1474-1784 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF
V600E
mutation. |
|---|---|
| AbstractList | In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation. In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation. In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation.In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation. |
| Audience | Academic |
| Author | Kirkpatrick, Peter Flaherty, Keith. T Yasothan, Uma |
| Author_xml | – sequence: 1 givenname: Keith. T surname: Flaherty fullname: Flaherty, Keith. T email: kflaherty@partners.org organization: Keith T. Flaherty is at Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA – sequence: 2 givenname: Uma surname: Yasothan fullname: Yasothan, Uma email: UYasothan@imscg.com organization: Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK – sequence: 3 givenname: Peter surname: Kirkpatrick fullname: Kirkpatrick, Peter email: p.kirkpatrick@nature.com organization: Peter Kirkpatrick is at Nature Reviews Drug Discovery |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22037033$$D View this record in MEDLINE/PubMed |
| BookMark | eNpt0U1PwyAYB3BiNDqn8Rt40INeqrwV6HExviUmXtQrAfrUYFo6oT347WXZ3OI0HCDkxx-eh0O0G_oACJ0QfEUwU9ch1qyU1Q6aEC55QaTiu-u1FAfoMKUPjIkgku6jA0oxk5ixCZq-QTdG00Dw9gjtNaZNcLyap-j17vbl5qF4er5_vJk9FY5jORRNVUppXV1CVRJqLQcuMGY1gKC1YpYoKxslhHNgFBYVBmltw0tihKXc1GyKLpa589h_jpAG3fnkoG1NgH5MusKEYU6VyPJsS370Ywz5cQukaJkrzOh8id5NC9qHph-icYtIPaOSMsExV1ld_aPyqKHzLnez8Xn_14HT1d2j7aDW8-g7E7_0T-8yKJbAxT6lCI12fjCD70NO9q0mWC_-Rq_-ZlP22v9E_pWXS5myCO8QN2Vv02_Md5bD |
| CitedBy_id | crossref_primary_10_1038_ng_3275 crossref_primary_10_1016_j_tranon_2025_102421 crossref_primary_10_1002_anie_201308743 crossref_primary_10_1016_j_ejmech_2018_12_040 crossref_primary_10_1016_j_bcp_2017_02_022 crossref_primary_10_1155_2016_2672671 crossref_primary_10_1093_ckj_sfv149 crossref_primary_10_1586_ern_12_111 crossref_primary_10_1111_pcmr_12020 crossref_primary_10_3390_cancers14133162 crossref_primary_10_1038_jid_2012_402 crossref_primary_10_4155_fmc_13_84 crossref_primary_10_1002_wsbm_1633 crossref_primary_10_1586_era_12_39 crossref_primary_10_1016_j_ajpath_2014_09_012 crossref_primary_10_1007_s12094_021_02644_3 crossref_primary_10_1016_j_bmcl_2012_07_039 crossref_primary_10_1097_PAS_0b013e3182753de6 crossref_primary_10_1208_s12249_018_0988_1 crossref_primary_10_1016_j_acra_2012_09_029 crossref_primary_10_1016_j_bbcan_2012_03_011 crossref_primary_10_1038_srep20253 crossref_primary_10_1002_med_21317 crossref_primary_10_1002_bmc_3672 crossref_primary_10_1016_j_yexmp_2014_09_001 crossref_primary_10_1097_CMR_0000000000000149 crossref_primary_10_1097_MD_0000000000000285 crossref_primary_10_1371_journal_pone_0057922 crossref_primary_10_3390_cells12141919 crossref_primary_10_1016_j_canlet_2016_10_025 crossref_primary_10_3109_10428194_2012_668188 crossref_primary_10_1016_j_bmcl_2020_127478 crossref_primary_10_1016_j_nbt_2012_03_010 crossref_primary_10_3390_molecules27072259 crossref_primary_10_3897_pharmacia_71_e111178 crossref_primary_10_3390_ijms222111726 crossref_primary_10_1016_j_bmc_2018_04_033 crossref_primary_10_1038_aps_2016_173 crossref_primary_10_1172_JCI62888 crossref_primary_10_2217_fon_14_265 crossref_primary_10_1111_exd_13089 crossref_primary_10_1038_nchem_1549 crossref_primary_10_1111_bcp_12651 crossref_primary_10_1007_s10585_012_9522_0 crossref_primary_10_1016_j_critrevonc_2019_05_016 crossref_primary_10_1016_j_disamonth_2024_101845 crossref_primary_10_3892_ol_2018_8614 crossref_primary_10_1038_nature12154 crossref_primary_10_1186_gm326 crossref_primary_10_1158_1078_0432_CCR_12_1177 crossref_primary_10_1002_pbc_24891 crossref_primary_10_1096_fj_202201217RR crossref_primary_10_1517_13543776_2012_728586 crossref_primary_10_1016_j_jinorgbio_2013_04_006 crossref_primary_10_3390_ijms22189741 crossref_primary_10_1038_nrclinonc_2012_160 crossref_primary_10_1042_BST20140030 crossref_primary_10_1016_j_clinthera_2012_06_009 crossref_primary_10_1515_psr_2018_0101 crossref_primary_10_1016_j_molonc_2012_01_011 crossref_primary_10_3389_fmolb_2024_1342179 crossref_primary_10_1002_adsc_202201384 crossref_primary_10_1016_j_kint_2021_08_022 crossref_primary_10_1093_carcin_bgx103 crossref_primary_10_1016_j_abb_2014_04_007 crossref_primary_10_1016_j_bcp_2014_12_003 crossref_primary_10_1016_j_biopha_2022_112967 crossref_primary_10_1111_j_1529_8019_2012_01487_x crossref_primary_10_1016_j_critrevonc_2024_104484 crossref_primary_10_1002_cpt_293 crossref_primary_10_1097_PAS_0b013e31824b1efd crossref_primary_10_1517_13543776_2013_749861 crossref_primary_10_1016_j_jaad_2012_04_008 crossref_primary_10_3892_mco_2013_97 crossref_primary_10_1016_j_ejmech_2022_114742 crossref_primary_10_1002_med_21255 crossref_primary_10_1016_j_clindermatol_2012_08_007 crossref_primary_10_1016_j_bpj_2018_01_016 crossref_primary_10_1097_PPO_0b013e31824d4465 crossref_primary_10_1186_1471_2407_13_581 crossref_primary_10_1186_1479_5876_10_15 crossref_primary_10_1007_s12033_024_01307_2 crossref_primary_10_1038_bjc_2014_342 crossref_primary_10_1038_srep45704 crossref_primary_10_12998_wjcc_v11_i15_3571 crossref_primary_10_1002_bimj_202000170 crossref_primary_10_1002_ange_201308743 crossref_primary_10_3389_fmolb_2022_834453 crossref_primary_10_3390_cancers10060157 crossref_primary_10_1002_hep_32574 crossref_primary_10_1080_17460441_2023_2254695 crossref_primary_10_1002_mc_22472 crossref_primary_10_1007_s10637_012_9883_x crossref_primary_10_1007_s11030_022_10545_y crossref_primary_10_3390_cancers14030664 crossref_primary_10_1590_s2175_97902018000001004 crossref_primary_10_1001_jamadermatol_2021_0024 crossref_primary_10_1038_jid_2014_425 crossref_primary_10_1080_2162402X_2017_1392426 crossref_primary_10_1038_nrclinonc_2011_192 crossref_primary_10_1016_j_comptc_2020_113026 crossref_primary_10_1093_ajcp_aqw115 |
| Cites_doi | 10.1056/NEJMoa1103782 10.1056/NEJMoa1003466 10.1056/NEJMoa1002011 10.1158/0008-5472.CAN-10-0118 10.1038/nature00766 10.1073/pnas.0711741105 10.1038/nature09454 10.1634/theoncologist.2010-0190 |
| ContentType | Journal Article |
| Copyright | Springer Nature Limited 2011 COPYRIGHT 2011 Nature Publishing Group Copyright Nature Publishing Group Nov 2011 |
| Copyright_xml | – notice: Springer Nature Limited 2011 – notice: COPYRIGHT 2011 Nature Publishing Group – notice: Copyright Nature Publishing Group Nov 2011 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1038/nrd3579 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Medical Database Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1474-1784 |
| EndPage | 812 |
| ExternalDocumentID | 2501436881 A272364048 22037033 10_1038_nrd3579 |
| Genre | News |
| GroupedDBID | --- 0R~ 123 29M 36B 39C 3V. 4.4 53G 70F 7RV 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AAEEF AARCD AAWYQ AAYOK AAYZH AAZLF ABAWZ ABDBF ABJNI ABLJU ABNNU ABUWG ACGFO ACGFS ACMJI ACRPL ACUHS ADBBV ADFRT ADNMO AENEX AFBBN AFKRA AFSHS AGAYW AGGDT AGHTU AHBCP AHMBA AHOSX AHSBF AIBTJ AIYXT ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH ARMCB ASPBG AVWKF AXYYD AZFZN B0M BENPR BKEYQ BKKNO BPHCQ BVXVI CCPQU CS3 DB5 DU5 EAD EAP EBS EE. EJD EMB EMK EMOBN EPL ESX EX3 EXGXG F5P FEDTE FQGFK FSGXE FYUFA HMCUK HVGLF HZ~ IAO IHR INH INR ITC L-9 LGEZI LOTEE M1P MK0 N9A NADUK NAPCQ NNMJJ NXXTH O9- ODYON P2P PQQKQ PROAC PSQYO Q2X RNR RNS RNT RNTTT SHXYY SIXXV SNYQT SOJ SV3 TAOOD TBHMF TDRGL TSG TUS UKHRP WOW ~8M AAYXX ABFSG AFANA AFFHD AGQPQ ALPWD ATHPR CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c407t-f9577bcd5e9512bb4e46003dee62d83b18b7f866ccea80690e7bbf451a6b24ad3 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 134 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000296592100015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1474-1776 1474-1784 |
| IngestDate | Sun Nov 09 10:31:39 EST 2025 Sun Nov 30 05:19:20 EST 2025 Tue Nov 11 10:26:41 EST 2025 Tue Nov 04 17:31:09 EST 2025 Mon Jul 21 06:04:42 EDT 2025 Sat Nov 29 03:31:53 EST 2025 Tue Nov 18 21:00:16 EST 2025 Fri Feb 21 02:37:25 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | http://www.springer.com/tdm |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c407t-f9577bcd5e9512bb4e46003dee62d83b18b7f866ccea80690e7bbf451a6b24ad3 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-News-1 content type line 14 content type line 23 |
| PMID | 22037033 |
| PQID | 901825147 |
| PQPubID | 27580 |
| PageCount | 2 |
| ParticipantIDs | proquest_miscellaneous_901304286 proquest_journals_901825147 gale_infotracmisc_A272364048 gale_infotracacademiconefile_A272364048 pubmed_primary_22037033 crossref_citationtrail_10_1038_nrd3579 crossref_primary_10_1038_nrd3579 springer_journals_10_1038_nrd3579 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-11-01 |
| PublicationDateYYYYMMDD | 2011-11-01 |
| PublicationDate_xml | – month: 11 year: 2011 text: 2011-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nature reviews. Drug discovery |
| PublicationTitleAbbrev | Nat Rev Drug Discov |
| PublicationTitleAlternate | Nat Rev Drug Discov |
| PublicationYear | 2011 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Flaherty (CR7) 2010; 363 Bollag (CR5) 2010; 467 Garbe (CR1) 2011; 16 Chapman (CR8) 2011; 364 CR6 Boni (CR9) 2010; 70 Tsai (CR4) 2008; 105 Hodi (CR2) 2010; 363 Davies (CR3) 2002; 417 PB Chapman (BFnrd3579_CR8) 2011; 364 C Garbe (BFnrd3579_CR1) 2011; 16 H Davies (BFnrd3579_CR3) 2002; 417 KT Flaherty (BFnrd3579_CR7) 2010; 363 A Boni (BFnrd3579_CR9) 2010; 70 J Tsai (BFnrd3579_CR4) 2008; 105 FS Hodi (BFnrd3579_CR2) 2010; 363 BFnrd3579_CR6 G Bollag (BFnrd3579_CR5) 2010; 467 20525992 - N Engl J Med. 2010 Aug 19;363(8):711-23 20818844 - N Engl J Med. 2010 Aug 26;363(9):809-19 21639808 - N Engl J Med. 2011 Jun 30;364(26):2507-16 18287029 - Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6 12068308 - Nature. 2002 Jun 27;417(6892):949-54 21212434 - Oncologist. 2011;16(1):5-24 20823850 - Nature. 2010 Sep 30;467(7315):596-9 20551059 - Cancer Res. 2010 Jul 1;70(13):5213-9 |
| References_xml | – volume: 364 start-page: 2507 year: 2011 end-page: 2516 ident: CR8 article-title: Improved survival with vemurafenib in melanoma with BRAF V600E mutation publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1103782 – volume: 363 start-page: 711 year: 2010 end-page: 723 ident: CR2 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1003466 – ident: CR6 – volume: 363 start-page: 809 year: 2010 end-page: 819 ident: CR7 article-title: Inhibition of mutated, activated BRAF in metastatic melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1002011 – volume: 70 start-page: 5213 year: 2010 end-page: 5219 ident: CR9 article-title: Selective BRAF inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-0118 – volume: 417 start-page: 949 year: 2002 end-page: 954 ident: CR3 article-title: Mutations of the gene in human cancer publication-title: Nature doi: 10.1038/nature00766 – volume: 105 start-page: 3041 year: 2008 end-page: 3046 ident: CR4 article-title: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0711741105 – volume: 467 start-page: 596 year: 2010 end-page: 599 ident: CR5 article-title: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma publication-title: Nature doi: 10.1038/nature09454 – volume: 16 start-page: 5 year: 2011 end-page: 24 ident: CR1 article-title: Systematic review of medical treatment in melanoma: current status and future prospects publication-title: Oncologist doi: 10.1634/theoncologist.2010-0190 – volume: 363 start-page: 711 year: 2010 ident: BFnrd3579_CR2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1003466 – volume: 16 start-page: 5 year: 2011 ident: BFnrd3579_CR1 publication-title: Oncologist doi: 10.1634/theoncologist.2010-0190 – volume: 105 start-page: 3041 year: 2008 ident: BFnrd3579_CR4 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0711741105 – volume: 364 start-page: 2507 year: 2011 ident: BFnrd3579_CR8 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1103782 – volume: 70 start-page: 5213 year: 2010 ident: BFnrd3579_CR9 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-0118 – ident: BFnrd3579_CR6 – volume: 467 start-page: 596 year: 2010 ident: BFnrd3579_CR5 publication-title: Nature doi: 10.1038/nature09454 – volume: 363 start-page: 809 year: 2010 ident: BFnrd3579_CR7 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1002011 – volume: 417 start-page: 949 year: 2002 ident: BFnrd3579_CR3 publication-title: Nature doi: 10.1038/nature00766 – reference: 18287029 - Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6 – reference: 20525992 - N Engl J Med. 2010 Aug 19;363(8):711-23 – reference: 20823850 - Nature. 2010 Sep 30;467(7315):596-9 – reference: 20818844 - N Engl J Med. 2010 Aug 26;363(9):809-19 – reference: 12068308 - Nature. 2002 Jun 27;417(6892):949-54 – reference: 21212434 - Oncologist. 2011;16(1):5-24 – reference: 20551059 - Cancer Res. 2010 Jul 1;70(13):5213-9 – reference: 21639808 - N Engl J Med. 2011 Jun 30;364(26):2507-16 |
| SSID | ssj0016172 |
| Score | 2.4217625 |
| Snippet | In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the... |
| SourceID | proquest gale pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 811 |
| SubjectTerms | 631/154 67 692/699/67/1813/1634 Animals Biomedical and Life Sciences Biomedicine Biotechnology Cancer Cancer Research Care and treatment Clinical trials Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Drug therapy fresh-from-the-pipeline Humans Indoles - pharmacology Indoles - therapeutic use Medicinal Chemistry Melanoma Melanoma - drug therapy Melanoma - enzymology Melanoma - genetics Metastasis Molecular Medicine Pharmacology/Toxicology Physiological aspects Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins B-raf - metabolism Ras genes Sulfonamides - pharmacology Sulfonamides - therapeutic use Vemurafenib |
| Title | Vemurafenib |
| URI | https://link.springer.com/article/10.1038/nrd3579 https://www.ncbi.nlm.nih.gov/pubmed/22037033 https://www.proquest.com/docview/901825147 https://www.proquest.com/docview/901304286 |
| Volume | 10 |
| WOSCitedRecordID | wos000296592100015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-1784 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016172 issn: 1474-1776 databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-1784 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016172 issn: 1474-1776 databaseCode: 7RV dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-1784 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016172 issn: 1474-1776 databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3JTtww9KkFDuVQWraGTamEphcsJnbGdk6IIhAHNBohQHOLvEVCajMwSyX-vn6OJwNTiUsvufjFcfxW-20Ax5U02p9lFaHWViRX3BKddRkxPPPnuKLrWIPpG9Hvy-GwGMTYnEkMq5zLxCCo7cjgHfmp11uYZZmLs6dngk2j0LkaO2h8hNUMTWNPzuL2oXUioHIOyUUiJ5kQvMmZxYrgp_XYsh6Gb71SRssi-ZVOWnKSBt1ztfGfq_4Cn6PRmZ43VPIVPrh6EzqDpmr1y0l6t0jCmpyknXSwqGf9sgXrD-73bKwqVz_qbbi_ury7uCaxhwIx_qg2JVXRE0Ib23PelKJa5y73Jg6zznFqJdOZ1KKSnBvjlMSqxU5oXeW9THFNc2XZDqzUo9p9g5RWkvHC86_LWK66rHC0spxq6vFppRIJdOabWZpYYBz7XPwqg6ObyTLuegJpC_jU1NT4F-QHYqNELvNzGBWTBfxKsF5VeU4FVr734ieBgzeQnjvMm-H9OWLKyJ2TssWKX0k7ii9iwFntRrMAghc9kiew21BBu1RKu8zLSZbA9zlZLKZe-o-9dz-_D5_CFXVIbTyAlel45g5hzfyZPk7GR4GY8TkU4SmPYPXnZX9w-xe-7f5h |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB6VggQcyhu2LbBIEC61mrUd23tAqAKqVg1RDgHltvVrpUqwKXm0yo_iP-LZV9ogceuBs2e9szvjGY_H8w3A21xZE2JZTahzOeFaOGKSLiNWJCGOS7ueVZLuy8FAjcfpcAN-N7UweK2ysYmloXYTi2fk-8FvYZUllx_PfxFsGoXJ1aaDRqUVJ355GSK22Yfjz0G87yg9_DL6dETqpgLEhthlTvK0J6WxrufD3oIawz0PPp857wV1iplEGZkrIaz1WiGMr5fG5LyXaGEo146FeW_B7WDGJcZ6ctzGdxgplMlVLjlJpBRVjS4ikO8XU8d6eF3sivNbdwFXfOBaUrb0dYcP_rO_9BC26k11fFCtgkew4YvH0BlWqNzLvXi0KjKb7cWdeLjC614-gfvf_c_FVOe-ODNP4duNMPoMNotJ4V9ATHPFRBrsk08Y112Wepo7QQ0N-uqUlhF0GuFltgZQxz4eP7Iykc9UVks5grglPK8wQ_4meY_Sz9CKhDmsroshAieIx5UdUInI_sG8RrB7jTKsfntteKdRhKy2PrOs1YLASTuKD-KFusJPFiUJHmQpEcHzSutaVintsuAHWARvGjVcTb32Hdv_fP1ruHs0-trP-seDkx24Vx7Hl2Wcu7A5ny78S7hjL-Zns-mrciHFcHrTOvkH_wRZMQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qU4TgwNqW0AJBguHSaCa2x3YOCBXaEVWrUYQK6i3Em1SJZsosVPPT-u94zjbtIHHrgbNfHCfv81vstwC8dVIr9GXziBjjIpZzE6m4TyPNY_Tjkr6lFaePxWgkT0-TdA2umlwYH1bZyMRSUJux9mfkPdRbPsuSiZ6royLS_eHHi1-RbyDlL1qbbhoVQo7s4hK9t-mHw31k9TtChgcnn79EdYOBSKMfM4tcMhBCaTOwaGcQpZhlqP-psZYTI6mKpRJOcq61zaUv6WuFUo4N4pwrwnJDcd47sC7QxmAdWP90MEq_tlcY3jQoU5sEi2IheJWx6-uR94qJoQMfPHZNFa4qhGsaceWKttR8w0f_8T97DA9rczvcq_bHE1izxVPoplW97sVueLJMP5vuht0wXVbyXjyDB9_t-XySO1ucqQ34disL3YROMS7scwiJk5QnKLlsTFnep4klznCiCCLZyFwE0G0Ymem6tLrv8PEzK6_4qcxqjgcQtoQXVTWRv0neeyRkXr7gHDqv0yRwJb5SV7ZHhK_5j4I3gJ0blCgX9I3h7QYUWS2XplmLCFxJO-of9KF2hR3PSxJ_xCV5AFsVAtulEtKnqCFoAG8aSC6nXvmOF_98_Wu4h1DMjg9HR9twvzynL_M7d6Azm8ztS7irf8_OppNX9a4K4cdtg_IPv19jUQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vemurafenib&rft.jtitle=Nature+reviews.+Drug+discovery&rft.au=Flaherty%2C+Keith+T&rft.au=Yasothan%2C+Uma&rft.au=Kirkpatrick%2C+Peter&rft.date=2011-11-01&rft.pub=Nature+Publishing+Group&rft.issn=1474-1776&rft.eissn=1474-1784&rft.volume=10&rft.issue=11&rft.spage=811&rft_id=info:doi/10.1038%2Fnrd3579&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=2501436881 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1474-1776&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1474-1776&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1474-1776&client=summon |